Premium
Drug‐induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity
Author(s) -
Shah Rashmi R.
Publication year - 2002
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1046/j.1472-8206.2002.00083.x
Subject(s) - agency (philosophy) , prolongation , labelling , food and drug administration , business , regulatory agency , drug approval , qt interval , control (management) , safety pharmacology , pharmacology , law and economics , medicine , political science , drug , psychology , anesthesia , public administration , cardiology , economics , sociology , management , criminology , social science
The views expressed in this paper are those of the author and do not necessarily represent the views or the opinions of Medicines Control Agency, other regulatory authorities or any of their advisory committees.